Contact
Payer
SUPPORT
fnsupport@mmitnetwork.com
267-751-3131
SALES
payersales@mmitnetwork.com
267-751-3161
Pharma
SUPPORT
support@mmitnetwork.com
267-751-3130
SALES
pharmasales@mmitnetwork.com
267-751-3162
Provider
SUPPORT
providersupport@mmitnetwork.com
267-751-3164
SALES
providersales@mmitnetwork.com
267-751-3163
Search this site on Google
Search Google
<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=29220&fmt=gif">
<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=29220&fmt=gif">
Formulary guidance and transparency from P&T to point of care
Payer
Manage
Guide
Publish
Pharma
Analyze
Promote
Assess
Provider
Search
Discover
Decide
Radar On Market Access: Evernorth Drug Trend Report Highlights Pandemic's Impact on Utilization
MMIT Reality Check on Acute Myeloid Leukemia (Apr 2021)
Trends That Matter for Partial Orphan Drugs
Radar On Market Access: Interoperability Mandate Could Be an Opportunity for Payers
Radar On Market Access: Study Highlights Promise of Bundled Payments in Employer Plans
MMIT Reality Check on COPD (Apr 2021)
Perspectives on Cigna's MDLive Deal
Radar On Market Access: PBM Regulation, Rebate Rule Are High on Legislative Agenda
Radar On Market Access: New Administration's Stance on Copay Accumulators Remains Unclear
MMIT Reality Check on HeFH (Mar 2021)
Trends That Matter for New Heart Failure Drugs
Radar On Market Access: Health Insurers May See Earnings Hit From COVID Vaccine Reimbursement Hike
Radar On Market Access: How Will Subsidy Expansion Impact ACA Marketplaces?
MMIT Reality Check on Immune Globulin (PID) (Mar 2021)
Perspectives on Stock Selloff Following CVS 4Q Earnings Report
Radar On Market Access: Orphan Drug Act Has Been Overused, A New Study Shows
Radar On Market Access: Ohio Names New Medicaid PBM, Sues One of Current Vendors
MMIT Reality Check on Non-Small Cell Lung Cancer EGFR Mutated (Mar 2021)
Trends That Matter for New Prostate Cancer Treatment
Radar On Market Access: Cigna's Evernorth to Acquire MDLive in Telehealth Expansion
Radar On Market Access: FDA's Breyanzi Approval May Not Change NHL Management
MMIT Reality Check on Crohn's Disease (Mar 2021)
Perspectives on Pass-Through Rebate Models
Radar On Market Access: 2020 Was 'Breakout Year' for Digital Engagement in Health Care
Radar On Market Access: New Heart Failure Drugs Offer More Therapy Options
MMIT Reality Check on HIV (Feb 2021)
Trends That Matter for Rx Benefits in Medicaid
Radar On Market Access: Analysts Downplay Stock Selloff Following CVS 4Q Earnings Report
Radar On Market Access: Aetna Plans to Return to ACA Exchanges
MMIT Reality Check on Type 2 Diabetes (GLP-1 and Combo) (Feb 2021)
Perspectives on Developments to Watch in Pharma
Radar On Market Access: Pass-Through Rebate Models Need to Demonstrate Value
Radar On Market Access: Publicly Traded Insurers Continue to Tout Pharmacy Divisions
MMIT Reality Check on Rheumatoid Arthritis (Feb 2021)
Trends That Matter for Prevention of HAE Attacks
Radar On Market Access: New Prostate Cancer Treatment Orgovyx Offers Oral Option
Radar On Market Access: Cigna, Humana Get Hit by Increased COVID-19 Costs in 4Q
MMIT Reality Check on Neutropenia (Feb 2021)
Perspectives on Centene, UnitedHealth M&A Activities
Radar On Market Access: More States Choose to Carve Out Medicaid Drug Benefits
Radar On Market Access: Vaccine Race, Regulatory Risk, Robust M&A Will Impact Drugmakers in 2021
MMIT Reality Check on Multiple Sclerosis (Jan 2021)
Trends That Matter for Epilepsy Medications' Market Access
Radar On Market Access: Though Care Utilization Rebounds, Insurers Still Face Uncertainty in 2021
Radar On Market Access: UnitedHealth: Health Care Spending Returned to Normal in 4Q
MMIT Reality Check on Macular Edema (Jan 2021)
Perspectives on Surprise Medical Billing Regulation
Radar On Market Access: PBMs Face More Regulatory Challenges Amid Chaotic Transition
Radar On Market Access: Centene to Bolster Pharmacy Services with Magellan Deal
MMIT Reality Check on Epilepsy (Jan 2021)
Trends That Matter for MCO's Role in COVID Vaccine Rollout
Radar On Market Access: Centene, UnitedHealth Ring in New Year With M&A
Radar On Market Access: FDA Approves First Oral Treatment for HAE Attack Prevention
MMIT Reality Check on Non-Small Cell Lung Cancer ALK+ or ROS1+ (Jan 2021)
Perspectives on New-to-Market Oral Drugs
Radar On Market Access: Supreme Court's ACA Ruling May Upend Biosimilars Market
Radar On Market Access: Despite New Approvals, Plans Still Favor Generics for Epilepsy
MMIT Reality Check on Metastatic Prostate Cancer (Dec 2020)
Trends That Matter for COVID Vaccine Distribution
Radar On Market Access: Surprise Medical Billing Comes to An End, Insurers Oppose Arbitration Mechanism
Radar On Market Access: PBMs Continue Integration, Face More Regulatory Challenges in 2020
MMIT Reality Check on Migraine Prevention (Dec 2020)
Perspectives on Amazon Pharmacy
Radar On Market Access: MCO Messaging Plays Key Role in COVID Vaccine Rollout
Radar On Market Access: Biden Probably Won't Roll Back New Prior Authorization Proposal
MMIT Reality Check on Breast Cancer HR+/HER2+ (Dec 2020)
Trends That Matter: Centene's ACA Expansion
Radar On Market Access: New-to-Market Oral Drugs May Not Always Have a Leg Up on Injectables
Radar On Market Access: First Round of Vaccines Are Expected to Be Free to the Public
MMIT Reality Check on Nonmetastatic Prostate Cancer (Dec 2020)
Perspectives on Biden Administration's Drug-Pricing Moves
Radar On Market Access: Employers Show Interest in Moving to ICHRAs
Radar On Market Access: Insurers Will Play Key Role in COVID Vaccine Distribution, Reimbursement
MMIT Reality Check on Ovarian Cancer (Dec 2020)
Trends That Matter for Growth Hormone Deficiency Treatments
Radar On Market Access: For PBMs, Amazon Pharmacy May Pose Only Indirect Threat
Radar On Market Access: MA Insurers Report Strong Performance, Predict Enrollment Growth
MMIT Reality Check on Type 2 Diabetes (DPP4 and Combo) (Nov 2020)
Perspectives on CMS Insulin Demo
Radar On Market Access: Teledermatology Program Reduces Patient Wait Time But Doesn't Increase Utilization
Radar On Market Access: Centene Expands ACA Footprint But Faces More Competition
MMIT Reality Check on Multiple Myeloma (Nov 2020)
Trends That Matter for Employer Health Benefits
Radar On Market Access: Insurer-Affiliated PBMs Propel Parent Firms' Revenues in Third Quarter
Radar On Market Access: Biden Administration's Drug-Pricing Moves May Be Limited
MMIT Reality Check on Cystic Fibrosis (Nov 2020)
Perspectives on MA Star Ratings
Radar On Market Access: What's Next for Health Insurers in a Likely Split Congress?
Radar On Market Access: Humana Reports Strong Earnings, But Expects Fourth-Quarter Loss
MMIT Reality Check on Chronic Lymphocytic Leukemia (Nov 2020)
Trends That Matter for Major PBMs' 2021 Formulary
Radar On Market Access: FDA's Approval of Sogroya May Change GH Class Management
Radar On Market Access: Centene Talks ACA's Future, Medicaid Rates in 3Q Earnings Call
MMIT Reality Check on Hepatocellular Carcinoma (Oct 2020)
Perspectives on the Future of ACA
Radar On Market Access: Employers Aim to Narrow Networks, Emphasize COEs, Expand Virtual Care Benefits
Radar On Market Access: Costlier PDPs, Cheaper MA-PDs Participate in CMS Insulin Demo
MMIT Reality Check on Psoriasis (Oct 2020)
Trends That Matter for CAR-T Therapies
Radar On Market Access: Racial Disparities Are Highlighted by Pandemic
Radar On Market Access: Average MA Star Ratings Fall Due to Increased Weights, Cut Points
MMIT Reality Check on Hemophilia A (Factor VIII) (Oct 2020)
Perspectives on Provider Consolidation
Radar On Market Access: Trump's $200 Medicare Drug Card Proposal Prompts Criticism
Radar On Market Access: CVS, OptumRx Exclude Brand-Name Inhalers From 2021 Formularies, Switch Up Diabetes Supplies
MMIT Reality Check on IBS-C (Oct 2020)
Trends That Matter on Trump Administration's Rebate Order
Radar On Market Access: COVID-19 Pandemic May Lower Health Care Costs, But Deferral Impact Exists
Radar On Market Access: If Preexisting Condition Protections Vanish, Health Insurers Probably Won't Cheer
MMIT Reality Check on Merkel Cell Carcinoma (Oct 2020)
Perspectives on Amazon-Sharp HealthCare Deal
Radar On Market Access: New Manufacturing Approach May Drive Down CAR-T Therapies' Prices
Radar On Market Access: Experts Remain Skeptical That SCOTUS Will Scuttle Entire ACA
MMIT Reality Check on Sickle Cell Disease (Sep 2020)
Trends That Matter for COVID Cost-Sharing Waivers
Radar On Market Access: Pandemic, Market Stability Encourage Major Insurers to Expand ACA Footprints
Radar On Market Access: As Payer M&A Slows Down, What's Next?
MMIT Reality Check on Schizophrenia (Sep 2020)
Perspectives on PBM Performance Amid COVID-19
Radar On Market Access: Prime Therapeutics Introduces Real Time Benefit Tool
Radar On Market Access: Trump's International Drug Pricing Order Is Still Missing; Rebate Order Draws Fire
MMIT Reality Check on Acute Migraine (Sep 2020)
Trends That Matter for Large Employers in 2021
Radar On Market Access: Amazon Moves Further Into Health Care Data, Sharp Deal Shows
Radar On Market Access: Some COVID Cost-Sharing Waivers Would Expire Soon
MMIT Reality Check on Breast Cancer HR+/HER2- (Sep 2020)
Perspectives on Telehealth Executive Order
Radar On Market Access: Insurers Expand Flu Vaccination Outreach to Blunt COVID-19 Effects
Radar On Market Access: USPS Delivery Slowdown Is Unlikely to Cause Major Rx Fill Disruption
MMIT Reality Check on Non-Small Cell Lung Cancer Systemic Therapy (Aug 2020)
Trends That Matter for Prostate Cancer Treatments
Radar On Market Access: Payers Face Challenges to Enroll Newly Uninsured
Radar On Market Access: Large Employers Expect Cost Uncertainty, More Virtual Care in 2021
MMIT Reality Check on Ulcerative Colitis (Aug 2020)
Perspectives on UnitedHealth, Humana's Chronic Conditions Programs
Radar On Market Access: COVID-19 Pandemic Amps Up Interest in Home Care
Radar On Market Access: Anthem, Cigna, CVS Report Strong PBM Performance Amid COVID-19
MMIT Reality Check on Duchenne Muscular Dystrophy (Aug 2020)
Trends That Matter for Major Insurers' Performance Amid COVID-19
Radar On Market Access: Trump Administration Issues Telehealth Executive Order, More Acts Are Needed
Radar On Market Access: FDA Approved Two PARP Inhibitors for Prostate Cancer
MMIT Reality Check on Parkinson's Disease (Aug 2020)
Perspectives on Remdesivir's $3,120 Price Tag
Radar On Market Access: Anthem Warns of Greater Commercial Enrollment Drop in Second Half
Radar On Market Access: Experts Are Skeptical of Trump Administration's Drug Pricing Executive Orders
MMIT Reality Check on Kidney Cancer (July 2020)
Trends That Matter for Medicaid MCOs
Radar On Market Access: UnitedHealth, Humana Launch Programs for Chronic Conditions
Radar On Market Access: Manufacturers, Payers Wait on Federal COVID-19 Vaccine Distribution Plan
MMIT Reality Check on Bipolar Disorder (July 2020)
Perspectives on Trump Admin's COVID-19 Testing Payment Guidance
Radar On Market Access: Despite Coronavirus Surge, UnitedHealth Expects Care Utilization to Rebound This Year
Radar On Market Access: Trump Admin's COVID-19 Testing Payment Guidance Stirs Debate
MMIT Reality Check on Psoriatic Arthritis (July 2020)
Trends That Matter for Racial Disparities in MA Plans
Radar On Market Access: IngenioRx Acquires ZipDrug to Improve Medication Adherence, Affordability
Radar On Market Access: Remdesivir's $3,120 Price Tag Stirs Debate
MMIT Reality Check on Acute Lymphoblastic Leukemia (July 2020)
Perspectives on MedImpact’s New Program to Accelerate Pharmacogenomics
Radar On Market Access: Upheld Transparency Rule Is Slated to Reshape Payer-Provider Negotiations
Radar On Market Access: Reports Show Medicaid MCOs Are 'Dominant,' Increase Affordability
MMIT Reality Check on Hemophilia A or B With Inhibitors (July 2020)
Trends That Matter for DMD Therapies
Radar On Market Access: Insurers Are Required to Cover Only 'Medically Necessary' COVID-19 Tests
Radar On Market Access: CMS Proposes New Medicaid Best Price Rules for Pricey Therapies
MMIT Reality Check on Ankylosing Spondylitis (June 2020)
Perspectives on COVID-19 Vaccine Rollout
Radar On Market Access: Telehealth Regulation and Reimbursement Issue Sparks Debates
Radar On Market Access: CMS Report Shows Increasing Racial Disparities in MA Plans
MMIT Reality Check on Urothelial/Bladder Cancer (June 2020)
Trends That Matter: Enrollment Shift Into ACA Exchanges
Radar On Market Access: Pricey Treatments Face Challenges on Cost Sharing and Data Analysis
Radar On Market Access: MedImpact’s New Program Aims to Accelerate Pharmacogenomics
MMIT Reality Check on Endometriosis (June 2020)
Perspectives on ACA Exchanges Amid COVID-19
Radar On Market Access: Uncertainties Over Effectiveness and High Costs Surround DMD Therapies
Radar On Market Access: 2021 MA, Part D Bids Face Challenges Amid COVID-19
MMIT Reality Check on Chronic Idiopathic Constipation (June 2020)
Trends That Matter: The Future of Value-Based Agreements
Radar On Market Access: 1.7K Plans Apply for Trump Admin's Fixed-Insulin-Copay Program for Seniors
Radar On Market Access: Payers and PBMs May Play Key Role in COVID-19 Vaccine Rollout
MMIT Reality Check on Narcolepsy (May 2020)
Perspectives on Surge of Mental Health Meds Use Amid COVID-19
Radar On Market Access: Will COVID-19 Advance Automatic Health Insurance Enrollment?
Radar On Market Access: COVID-19 Pandemic May Change Rx Delivery Permanently
MMIT Reality Check on Low Testosterone (May 2020)
Trends That Matter for Medical-Benefit Drug Spending
Radar On Market Access: COVID-19 Pandemic Drives Home Infusion Utilization
Radar On Market Access: PBMs See Solid 1Q Results Despite Challenges Ahead
MMIT Reality Check on Pain Narcotic Opioid (May 2020)
Perspectives on Coronavirus Antibody Testing
Radar On Market Access: COVID-19 May Drive More Insurers Into ACA Exchanges
Radar On Market Access: CVS Sees COVID Testing Sites as Part of Bigger HealthHUB Strategy
MMIT Reality Check on Anemia — Chronic Kidney Disease (May 2020)
Trends That Matter for Biosimilar Medications Cost Savings
Radar On Market Access: Anthem, Cigna Brace for Recession-Induced Enrollment Shift
Radar On Market Access: Humana, Centene Maintain 2020 Earnings Outlook Amid COVID-19 Pandemic
MMIT Reality Check on Ophthalmic Anti-Inflammatory (Apr 2020)
Perspectives on ACA and Medicaid Enrollment Growth Amid COVID-19
Radar On Market Access: Oncology Drugs Drive Price Growth in Medical-Benefit Spend
All posts
Learn more about MMIT's solutions
Posts by Topic
Industry Trends
(588)
Market Access
(582)
Payer
(582)
Specialty
(419)
Branding & Marketing
(308)
Provider
(288)
Data & Analytics
(260)
Product Release
(83)
see all
Recent Posts
Subscribe to our blog